Advertisement


Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

COVID-19 and Cancer Care

Advertisement

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.



Related Videos

Global Cancer Care
COVID-19

Giorgio V. Scagliotti, MD, PhD, on the Oncoming Waves of COVID-19: Italy’s Experience

Giorgio V. Scagliotti, MD, PhD, of the University of Turin, talks about the progression of COVID-19 through his community and how, in nursing homes, lack of experience dealing with a pandemic is fueling a third wave of the virus in Italy. Filmed April 15, 2020.

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 4

For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19?

Recorded April 24, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 3

During the COVID-19 pandemic, would you still recommend immediate upfront autologous transplant in patients with T-cell non-Hodgkin lymphoma?

Recorded April 21, 2020.

COVID-19
Hematologic Malignancies

Mehdi Hamadani, MD: In My Experience Question 4

How have the activities of the Center for International Blood and Marrow Transplant Research been affected by the COVID-19 pandemic?

Recorded April 21, 2020.

COVID-19

Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations

Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.

Advertisement

Advertisement




Advertisement